TC-510 drug page Clinical trials

Trials with TC-510

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

1Trials
0Recruiting
1Countries
6Planned patients

Showing 1–1 of 1

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Finished Phase 1 6 patients NCT05451849

TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon e…

United States Jun 2022 – Oct 2028 Interventional